Siemens Fonds Invest GmbH Boosts Position in AbbVie Inc. (NYSE:ABBV)

Siemens Fonds Invest GmbH increased its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 197.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 179,440 shares of the company's stock after purchasing an additional 119,141 shares during the period. Siemens Fonds Invest GmbH's holdings in AbbVie were worth $32,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Tallon Kerry Patrick acquired a new position in AbbVie in the 4th quarter valued at about $309,000. Capital & Planning LLC increased its holdings in shares of AbbVie by 1.7% in the fourth quarter. Capital & Planning LLC now owns 6,239 shares of the company's stock valued at $1,109,000 after purchasing an additional 105 shares during the period. Ameritas Advisory Services LLC raised its stake in shares of AbbVie by 18.0% during the fourth quarter. Ameritas Advisory Services LLC now owns 23,936 shares of the company's stock worth $4,254,000 after purchasing an additional 3,657 shares during the last quarter. Aaron Wealth Advisors LLC lifted its holdings in shares of AbbVie by 6.5% during the fourth quarter. Aaron Wealth Advisors LLC now owns 10,719 shares of the company's stock worth $1,905,000 after purchasing an additional 651 shares during the period. Finally, Stillwater Capital Advisors LLC grew its position in AbbVie by 1.1% in the 4th quarter. Stillwater Capital Advisors LLC now owns 90,816 shares of the company's stock valued at $16,138,000 after buying an additional 1,018 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at AbbVie

In related news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the business's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $210.08, for a total value of $12,359,426.56. Following the completion of the sale, the executive vice president now directly owns 53,234 shares in the company, valued at approximately $11,183,398.72. The trade was a 52.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy J. Richmond sold 29,917 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the transaction, the executive vice president now directly owns 44,284 shares in the company, valued at approximately $8,985,223.60. This represents a 40.32% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 107,693 shares of company stock worth $22,282,985. 0.25% of the stock is currently owned by insiders.

AbbVie Trading Up 0.3%

NYSE:ABBV traded up $0.52 on Thursday, reaching $182.32. The stock had a trading volume of 4,684,698 shares, compared to its average volume of 6,253,258. AbbVie Inc. has a 12-month low of $153.58 and a 12-month high of $218.66. The company has a market cap of $322.05 billion, a price-to-earnings ratio of 75.97, a P/E/G ratio of 1.62 and a beta of 0.56. The firm's fifty day moving average is $189.64 and its two-hundred day moving average is $186.68. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.40 by $0.06. The business had revenue of $13.34 billion for the quarter, compared to the consensus estimate of $12.91 billion. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The company's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.31 earnings per share. Equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Analysts Set New Price Targets

ABBV has been the subject of a number of analyst reports. Erste Group Bank upgraded shares of AbbVie to a "strong-buy" rating in a research report on Monday, March 17th. Bank of America increased their price target on shares of AbbVie from $200.00 to $223.00 and gave the stock a "neutral" rating in a report on Tuesday, March 4th. The Goldman Sachs Group restated a "neutral" rating and issued a $194.00 price objective on shares of AbbVie in a research report on Tuesday, April 8th. BNP Paribas upgraded AbbVie to a "hold" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a report on Thursday. Eight research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $210.95.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.